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Abstract 
Introduction: Limited data exist on clinical characteristics and outcomes of hospitalized COVID-19 patients in low-middle income countries. 
We aimed to describe the clinical spectrum and outcomes of hospitalized COVID-19 patients at a tertiary-care center in Karachi, Pakistan. 
Methodology: We conducted an observational study of adult COVID-19 patients hospitalized between February-June 2020. Patients with a 
discharge diagnosis of COVID-19 and PCR positivity were included. We created logistic regression models to understand association of clinical 
characteristics with illness severity and in-hospital mortality. 
Results: The study population comprised 445 patients [67% males, median age 53 (IQR 40-64) years]. Majority of patients (N = 268; 60%) 
had ≥ 1 co-morbid [37.5% hypertension, 36.4% diabetes]. In-hospital mortality was 13%. Age ≥ 60 (aOR] =1.92; 95 %CI = 1.23-3.03), 
shortness of breath (aOR=4.43; 95% CI=2.73-7.22), CRP ≥150mg/L (aOR:1.77; 95% CI=1.09-2.85), LDH ≥ 500 I.U/L (aOR:1.98; 95% 
CI=1.25-3.16), Neutrophil-to-Lymphocyte ratio (NLR) ≥5 (aOR:2.80; 95%CI = 1.77-4.42) and increase in serum creatinine (aOR:1.32; 
95%CI=1.07-1.61) were independently associated with disease severity. Septic shock (aOR: 13.27; 95% CI=3.78-46.65), age ≥ 60 (aOR: 3.26; 
95% CI=1.07-9.89), Ferritin ≥ 1500ng/ml (aOR: 3.78; 95% CI=1.21-11.8), NLR ≥ 5 (aOR: 4.04; 95% CI=1.14-14.35) and acute kidney injury 
(aOR: 5.52; 95% CI=1.78-17.06) were independent predictors of in-hospital mortality. 
Conclusions: We found multiple predictors to be independently associated with in-hospital mortality, except diabetes and gender. Compared 
to reports from other countries, the in-hospital mortality among COVID-19 patients was lower, despite a high burden of co-morbidities. Further 
research is required to explore reasons behind this dichotomy. 
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Introduction 
Rapidly evolving data on COVID-19 from across 
the globe show that its disease severity and mortality 
are heterogeneous. The proportion of severely ill 
patients presenting to the hospital and in-hospital 
mortality of COVID-19 has been invariably high. Initial 
reports from the United Kingdom showed an in-hospital 
mortality was 26% in the 17% of patients admitted with 
severe to critical disease [1]. Similarly in the United 
States up to 25% of hospitalized patients were critically 
ill and the in-hospital mortality ranged from 21% to 
25% [2,3]. These data cannot be imputed or used as a 
surrogate for low middle-income countries due to the 
inherent differences in population health care access, 
immunity and, high background burden of 
communicable and non-communicable diseases. Data 
on hospitalized patients from developing countries are 
now being reported from tertiary care centers in the 
region. A study from Bangladesh has reported a 28-day 
mortality of 2.5% with a greater risk of death among 
elderly with co-morbid conditions [4]. Studies from 
India have shown that up to 14% of symptomatic 
patients developed a severe illness and the in-hospital 
mortality ranged was 4.5 to 5% with similar risk factors 
as those reported from Bangladesh [5,6]. A Single-
center study from Egypt reported a greater incidence of 
hospitalization and severity in patients with an age of 
greater than 50 years [7]. Limited data have been 
reported from small studies in Pakistan largely confined 
to intensive care settings [8,9]. An elaborate 
understanding of clinical characteristics and outcomes 
of hospitalized COVID-19 patients in low-middle 
income countries (LMICs) represents an important 
knowledge gap given the heterogeneity of data from 
these countries [10]. Bridging this knowledge gap is 
necessary for increasing our understanding of the risks 
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and designing interventions for managing the most 
susceptible patients. To address this gap we evaluated 
clinical, biochemical, and radiological features and 
outcomes of COVID-19 in a larger cohort of 445 
patients at an academic medical center in Karachi with 
a dedicated facility for COVID-19. 
 
Methodology 
Study population and Design 
We conducted an observational study of adult 
COVID-19 patients hospitalized at the dedicated 
COVID-19 facility at the Aga Khan University Hospital 
between February 26 and June 10, 2020. We included 
all adult patients (≥ 18 years old) who had a discharge 




We first curated a list of all patients hospitalized 
with a discharge diagnosis and positive PCR test for 
COVID-19 through the Hospital information 
management system. A detailed chart review was then 
conducted to extract demographics, clinical 
characteristics, outcomes, and treatment details of 
confirmed COVID-19 patients including underlying co-
morbidities, laboratory and radiological investigations, 
and complications during hospitalization using a 
structured proforma. Patients were stratified based on 
the severity of illness which was defined as follows: a) 
Asymptomatic/Mild Illness: Patients who are either 
symptom-free or symptomatic COVID-19 patients who 
do not have hypoxia; b) Moderate Illness: Patients with 
evidence of lower respiratory disease during clinical 
assessment or imaging and who have a saturation of 
oxygen (SpO2) ≥90% on room air; c) Severe/Critical 
Illness: Patients with any of the following: SpO2 < 90% 
on room air, PaO2/FiO2 < 300 mm Hg, respiratory 
frequency >30 breaths/min, or > 50% infiltrates on 
chest radiograph and/or any of complications including 
respiratory failure/ARDS, septic shock, and/or multiple 
organ dysfunction. 
 
Diagnosis of COVID-19 
All included patients underwent nasopharyngeal 
swabs which were processed for detection of SARS-
Cov-2 virus by real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) using the WHO 
protocol for the 2019- nCoV RT-PCR assay in March 
2020. Specimens in May were tested using the Cobas® 
SARS-CoV-2 RT-PCR assay (Roche Diagnostics, 
Indianapolis, IN, USA). A radiological diagnosis of 
pneumonia was made by evaluation of infiltrates 
observed on chest radiographs and/or CT chest. A 
multidisciplinary team of doctors including infectious 
disease consultants, pulmonologists, and intensivists 




Descriptive analysis was performed for 
demographic features with mean and standard deviation 
or median with interquartile range (IQR) reported for 
quantitative variables such as age and lengths of 
hospital stay as appropriate. Frequencies (percentage) 
for qualitative variables such as gender, co-morbid 
conditions, mortality, and complications. Continuous 
variables were also transformed into categorical 
variables for further analysis as indicated. χ2 test of 
independence or Fischer exact test was performed for 
categorical variables such as comparison of those with 
COVID-19 who died with those who were discharged. 
We created univariable and multivariable logistic 
regression models to understand the association of risk 
factors associated with illness severity of COVID-19, 
(mild, moderate, and severe/critical). To identify 
factors independently associated with death in COVID-
19 infection we created a stepwise multivariable 
logistic regression model. The model included variables 
found to be significant on univariable analysis and those 
deemed of clinical relevance. Unadjusted and adjusted 
odds ratios were reported. We included interaction 
terms to understand the interaction between age and 
gender. Significance was set at a value ≤0.05. STATA 
Version 12.1was used for data analysis. 
 
Ethics approval 
This study received approval from the Aga Khan 
University Ethics Review Committee of the hospital 
(ERC reference number: 2020-3650-11773). The data 
was collected from hospital records and the requirement 
for informed consent was waived by the hospital ethical 
review committee as data was anonymized and no 
personal identifiers were collected. 
 
Results 
Demographics, Clinical characteristics, and course of 
the disease 
Of a total of 11,393 adult patients admitted to the 
Aga Khan University Hospital between Feb 26, 2020, 
and June 10, 2020, 445 (3.9%) patients were diagnosed 
with COVID-19 based on RT-PCR positivity for 
SARS-CoV-2. Most of the hospitalized COVID-19 
patients were male (298, 67%). The median age of the 
cohort was 53 years (IQR 40 – 64 years). Age was 
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further categorized into groups: 11.7% (N = 52) of the 
patients were between 18 and 29 years of age, 12.8% 
(N = 57) between 30 and 39 years, 18.4% (N = 84) 
between 40 and 49 years, 23.1% (N = 103) between 50 
and 59 years, 18.8% (N = 84) between 60 and 69 
years,11.5% (N = 51) between 70 and 79 years, and 
3.6% (N = 16) of the patients were greater than 80 years 
of age. 
A total of 55 patients were (12.4%) asymptomatic 
and 137 (30.8%) had severe/critical disease. Most (268; 
60.2%) patients had at least one or more than one co-
morbidity, of which hypertension was the most 
common (37.5%) followed by diabetes (36.4%). 
Among symptomatic patients (n= 390, 87.6%), the most 
common symptom was fever (80%) followed by cough 
(61.3%) and shortness of breath (61.0%). The median 
duration of illness prior to presentation was 7 days (IQR 
3-10) and was longer with worsening severity of illness 
(median of 3 days in mild, 7 days in moderate and 
severe each). Admissions peaked in May and then 
steadily reduced over time. The proportion of patients 
with severe disease increased with time; in March, 25% 
of admitted patients were severely ill and in May 34% 
of admitted patients had severe disease. Despite the 
increasing severity, the proportion of in-hospital 
mortality increased in May and started to decline in 
June (Figure 1). The median C-reactive protein (CRP) 
level was 83.3 mg/L (IQR: 27.8 -178.9) and the median 
ferritin level was 551 ng/ml (IQR: 254.1-1258.3). 
Overall, 124 (27.9%) required non-invasive ventilation 
(NIV) and 64 (14.5%) required invasive positive 
pressure (IPPV) ventilation. Chest X-rays were 
performed in 432 patients (97%). Chest X-rays were 
normal in 21.57% of patients. Unilateral involvement 
was seen less frequently as compared to bilateral 
disease (7.7% vs 66% respectively). Treatment received 
varied as the protocols changed with chloroquine use 
dropping from 2.25% of patients to zero between 
February and April. Similarly, hydroxychloroquine was 
given to 31% of patients overall with use declining from 
47% to 2.1% between April and June. Among 
antivirals; nine patients received oseltamivir and two 
patients received lopinavir/ritonavir. Systemic steroids 
and intravenous tocilizumab were administered to 
moderate to severely ill patients with hypoxia and 
laboratory evidence of hyperinflammation. Overall, 
56% of the patients (N=249) received systemic steroids 
and 19.3% (N=86) received intravenous tocilizumab 
during hospitalization. Sixty-eight patients (15%) 
required ICU admission. Septic shock was seen in 62 
(14%) of the cases while 44 (9.9%) presented in multi-
organ dysfunction. Acute kidney injury was seen in 96 
(21.6%) and 46 (10.3%) patients presented with a 
Figure 1. Weekly time plot of hospital admissions according to 
severity of disease, showing predominance of mild cases in week 
2 and 3 after the first reported case, with subsequent rise of 
severe cases peaking at week 11 and 12. At week 14, a week 
before the sharp decline over the peak of the curve, severe cases 
decline and there are predominantly mild cases. 
Table 1. Comparison of mild, moderate and severe COVID-19 patients admitted at tertiary care center in Karachi, Pakistan. 
Variables All  (N = 445) 
Mild  
(N = 156) 
Moderate  
(N = 152) 
Severe  
(N = 137) p-value 
Age* (mean ± SD) 51.6 ± 16.1 42.3 ± 16.2 54.0 ± 12.7 59.4 ± 14.1 < 0.001 
Gender⁕      
Male 298 (67%) 86 (55.1%) 108 (71.1%) 105 (76.6%) < 0.001 
Female 147 (33%) 70 (44.9%) 44 (28.9%) 32 (23.4%)  
Duration of illness⁕ [median (IQR) 
days] 7 (3-10) 3 (0-7) 7 (5-10) 7 (5-10) < 0 .001 
Co-morbids      
Diabetes⁕ 162 (36.4%) 28 (17.9%) 70 (46.1%) 64 (46.7%) < 0.001 
Hypertension⁕ 167 (37.5%) 30 (19.2%) 65 (42.8%) 72 (52.6%) < 0.001 
Ischemic heart disease⁕ 74 (16.6%) 10 (6.4%) 25 (16.4%) 39 (28.5%) < 0.001 
Chronic kidney disease⁕ 31 (7%) 2 (1.3%) 13 (8.6%) 16 (11.7%) 0.001 
Malignancy 22 (4.9%) 8 (5.1%) 5 (3.3%) 9 (6.6%) 0.601 
Stroke⁕ 10 (2.2%) 0 (0%) 3 (2%) 7 (5.1%) 0.007 
Chronic liver disease 8 (1.8%) 4 (2.6%) 1 (0.7%) 3 (2.2%) 0.739 
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myocardial infarction alone. Secondary infections were 
common and occurred in 59 (13.3%) of patients.  
 
  
Table 1 (continued). Comparison of mild, moderate and severe COVID-19 patients admitted at tertiary care center in Karachi, Pakistan. 
Variables All  (N = 445) 
Mild  
(N = 156) 
Moderate  
(N = 152) 
Severe  
(N = 137) p-value 
Symptoms      
Fever⁕ 312 (70.1%) 83 (53.2%) 126 (82.9%) 103 (75.2%) < 0.001 
Cough⁕ 239 (53.7%) 56 (35.9%) 103 (67.8%) 80 (58.4%) < 0.001 
Shortness of breath⁕ 238 (53.5%) 24 (15.4%) 100 (65.8%) 114 (83.2%) <0 .001 
Sore throat⁕ 48 (10.8%) 22 (14.1%) 18 (11.8%) 8 (5.8%) 0.028 
Myalgias 52 (11.7%) 21 (13.5%) 16 (10.5%) 15 (10.9%) 0.736 
Radiologic findings      
Normal⁕ 96 (21.6%) 93 (59.6%) 3 (2%) 1 (0.7%) < 0.001 
Bilateral involvement⁕ 291 (65.4%) 32 (20.5%) 133 (87.5%) 126 (92%) < 0.001 
Unilateral involvement 34 (7.6%) 10 (6.4%) 17 (11.2%) 7 (5.1%) 0.733 
Patchy infiltrates⁕ 293 (65.8%) 33 (21.2%) 137 (90.1%) 123 (89.8%) < 0.001 
Multilobar involvement⁕ 178 (40%) 14 (9%) 85 (55.9%) 79 (57.7%) < 0.001 
Consolidation⁕ 48 (10.8%) 7 (4.5%) 18 (11.8%) 23 (16.8%) 0.001 
CURB score⁕ [median (IQR)] 1 (0-2) 0 (0) 1 (0-1) 2 (1-3) < 0.001 
Laboratory Investigations      
C-Reactive Protein⁕ <150 mg/L 252 (56.6%) 96 (61.5%) 105 (69.1%) 51 (37.2%) <0.001 
C-Reactive Protein >=150 mg/L 193 (43.4%) 60 (38.5%) 47 (30.9%) 86 (62.8%)  
LDH⁕ <500 IU/L 235 (52.8%) 81 (51.9%) 109 (71.7%) 45 (32.8%) 0.003 
LDH>=500 IU/L 210 (47.2%) 75 (48.1%) 43 (28.3%) 92 (67.2%)  
Neutrophil to lymphocyte ratio⁕ <5 255 (57.3%) 118 (75.6%) 95 (62.5%) 42 (30.7%) <0.001 
Neutrophil to lymphocyte ratio   >=5 190 (42.7%) 38 (24.4%) 57 (37.5%) 95 (69.3%)  
Ferritin <1500 ng/ml 249 (56%) 84 (53.8%) 104 (68.4%) 61 (44.5%) 0.162 
Ferritin>=1500 ng/ml 196 (44%) 72 (46.2%) 48 (31.6%) 76 (55.5%)  
Type of Ward      
ICU Admission⁕ 68 (15.3%) 0 (0%) 1 (0.7%) 67 (48.9%) < 0.001 
SCU Admission⁕ 148 (33.3%) 12 (7.7%) 75 (49.3%) 61 (44.5%) < 0.001 
Ward admission⁕ 223 (50.1%) 141 (90.4%) 76 (50%) 6 (4.4%)i < 0.001 
Treatment      
Non-invasive ventilation⁕ 124 (27.9%) 0 (0%) 35 (23%) 89 (65%) < 0.001 
Invasive ventilation⁕ 64 (14.4%) 0 (0%) 0 (0%) 64 (46.7%) < 0.001 
Oxygen support⁕ 278 (62.5%) 8 (5.1%)ii 135 (88.8%) 135 (98.5%) < 0.001 
Antibiotics⁕ 236 (53%) 25 (16%) 86 (56.6%) 125 (91.2%) < 0.001 
Azithromycin⁕ 164 (36.9%) 16 (10.3%) 68 (44.7%) 80 (58.4%) < 0.001 
Hydroxychloroquine⁕ 139 (31.2%) 11 (7.1%) 67 (44.1%) 61 (44.5%) < 0.001 
Chloroquine 10 (2.2%) 1 (0.6%) 4 (2.6%) 5 (3.6%) 0.093 
Tocilizumab⁕ 86 (19.3%) 0 (0%) 21 (13.8%) 64 (46.7%) < 0.001 
Oseltamivir⁕ 9 (2%) 0 (0%) 3 (2%) 6 (4.4%) 0.014 
Lopinavir/Ritonavir 3 (0.7%) 0 (0%) 1 (0.7%) 2 (1.5%) 0.161 
Systemic steroids⁕ 249 (56%) 6 (3.8%)iii 120 (78.9%) 123 (89.8%) < 0.001 
Vasopressors⁕ 59 (13.3%) 0 (0%) 1 (0.7%) 58 (42.3%) < 0.001 
Complications      
ARDS⁕ 122 (27.4%) 0 (0%) 19 (12.5%) 103 (75.2%) < 0.001 
Septic Shock⁕ 62 (13.9%) 0 (0%) 0 (0%) 62 (45.3%) < 0.001 
MODS⁕ 44 (9.9%) 0 (0%) 3 (2%) 41 (29.9%) < 0.001 
Nosocomial Infection⁕ 59 (13.3%) 1 (0.6%) 10 (6.6%) 48 (35%) < 0.001 
AKI⁕ 96 (21.6%) 5 (3.2%) 21 (13.8%) 70 (51.1%) < 0.001 
NSTEMI⁕ 46 (10.3%) 1 (0.6%) 9 (5.9%) 36 (26.3%) < 0.001 
Length of stay⁕ [median (IQR) days 5 (3-9) 3 (2-5) 6 (4-9) 8 (5-14) < 0.001 
Dead⁕ 58 (13%) 0 (0%) 3 (2%) 55 (40.1%) < 0.001 
Discharged 360 (80.9%) 144 (92.3%) 142 (93.4%) 74 (54%)  
Left against medical advice (LAMA) 27 (6.1%) 12 (7.7%) 7 (4.6%) 8 (5.8%)  
⁕ significant at p-value < 0.05; i:These were patients with severe disease admitted for comfort care;  ii: This includes patient who had polytrauma, hematemesis, 
gastrointestinal bleed etc. who were incidentally diagnosed with COVID-19; iii:These were varied, one with underlying malignancy, one with penumoperitoneum 
who was found on preop screening, a couple had raised ferritin only. 
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ICU mortality was 58.8% (40/68). A total of 58 patients 
died with an overall mortality rate of 13%. (Table 1). 
 
Comparison of Severe, moderate, and mild disease 
In all, 35% of patients had asymptomatic/mild 
disease, 34% moderate, and 30% had severe/critical 
disease on admission. Compared with patients with 
asymptomatic/mild and moderate disease, patients with 
severe disease were older, (severe disease: mean 59 
years vs mild disease 42 years); and were likely to have 
co-morbidities such as diabetes, hypertension, and 
ischemic heart disease (p-value < 0.001).  
A greater proportion of patients with severe disease 
had shortness of breath (83%) on presentation. Chest 
radiographic with bilateral peripheral opacities were 
seen in majority of the patients with moderate (87.5%) 
and severe disease (92%) whereas most of the mildly 
diseased patients (60%) had a normal chest x-ray. 
Patients with greater severity of illness had significantly 
higher median CRP, ferritin, LDH, and D-Dimer values 
as well as a higher mean neutrophil to lymphocyte ratio 
compared to those with mild and moderate disease (p-
value < 0.001). Hydroxychloroquine was given to 44% 
patients with moderate and 44% patients with severe 
disease respectively. Intravenous steroids were used in 
majority of the patients with moderate and severe 
disease (79% and 90% respectively). Intravenous 
Tocilizumab was administered to 86 (19.3%) cases and 
predominantly among those with severe disease 
(47.4%). Antibiotic use was common in severe disease 
with 91% receiving any antibiotics as opposed to16.5% 
of the mild and 57% of moderate cases. 
 
Associations of Severity of Illness 
Ordinal logistic regression was performed to 
determine predictors of severity (Table 2). 
Multivariable ordinal regression analysis revealed that 
the risk of having severe disease was 1.92 (95% CI: 
1.23 -3.03) times higher in patients with age ≥ 60 years 
of age when compared with patients < 60 years. 
Presence of shortness of breath at presentation (OR = 
4.43; 95% CI: 2.73-7.22) and presence of bilateral 
peripheral opacities on chest radiograph was associated 
with greater severity of illness (OR=5.81; 95% CI: 
2.90-11.62). Among laboratory investigations done on 
admission; the risk of greater severity of illness was 
associated with CRP ≥ to 150mg/L (OR=1.77; 95% CI: 
1.10-2.85), LDH ≥ 500 I.U/L (OR=1.98; 95% CI: 1.25-
3.16), Neutrophil to Lymphocyte ratio ≥ 5 (OR = 2.80; 
95% CI: 1.77-4.42) and a unit increase in serum 
creatinine level in mg/dl (OR=1.32; 95% CI: 1.07-
1.61). None of the treatment modalities had any 
statistically significant impact on the severity of illness. 
 
Factors associated with odds of death 
Univariable predictors of death included older age, 
male sex, co-morbid conditions, and presence of 
complications such as septic shock, multi-organ 
dysfunction, acute kidney injury, myocardial infarction, 
and nosocomial infections (Table 3). Majority of the 
patients who died (69%) had been admitted to the ICU. 
There was only one death in the ward due to an 
underlying malignancy. All of the 17 patients who died 
in the High Dependency Units had a code status of was 
either Do-Not-Resuscitate (DNR) or comfort care due 
to an underlying terminal illness.   
Table 2. Multivariable ordinal logistic regression for factors associated with level of severity. 
Variable Categories OR 95% CI p-value 
Age < 60 years (Ref) 1   
 > = 60 years 1.93 1.23-3.03 0.004 
Shortness of breath Absent (Ref) 1   
 Present 4.44 2.73-7.22 < 0.001 
Bilateral chest radiographic findings Absent (Ref) 1   
 Present 3.13 1.58- 6.17 0.001 
Patchy infiltrates Absent (Ref) 1   
 Present 5.81 2.90-11.6 < 0.001 
C-Reactive Protein < 150 (Ref) 1   
 > = 150 1.77 1.09-2.85 0.019 
Lactate dehydrogenase < 500(Ref) 1   
 > = 500 1.98 1.25-3.16 0.004 
Neutrophil to lymphocyte ratio < 5 (Ref) 1   
 > = 5 2.80 1.77-4.42 < 0.001 
Creatinine* on admission  1.32 1.07-1.61 0.008 
*per unit increase. 
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Table 3. Risk Factors associated with mortality. 
Variables Died (N = 58) 
Recovered 
(N = 360) 
Univariable OR 
(95% CI) p-value 
Multivariable OR 
(95% CI) p-value 
Age groups⁕⁕       
< 60 years (Ref) 23 257 1  1  
> = 60 years 35 103 3.79 (2.14-6.74) < 0.001 3.26 (1.07-9.89) 0.037 
Gender⁕       
Female (Ref) 11 130 1    
Male 47 230 2.42 (1.21-4.82) 0.012   
Co-morbids (present vs. not present)      
Diabetes⁕ 28 124 1.78 (1.02-3.11) 0.044   
Hypertension⁕ 31 124 2.18 (1.25-3.83) 0.006   
Ischemic heart disease⁕ 20 50 3.26 (1.76-6.06) < 0.001   
CKD⁕ 12 17 5.26 (2.36-11.72) < 0.001   
Malignancy⁕ 7 12 3.98 (1.50-10.58) 0.006   
Radiologic findings (present vs. absent)      
Bilateral patchy infiltrates⁕ 52 224 5.14 (2.15- 12.30) < 0.001   
Laboratory investigations       
NLR⁕⁕       
< 5 (ref) 15 227 1    
> = 5 43 133 4.89 (2.62-9.14) < 0.001 4.04 (1.14-14.35) 0.031 
Ferritin ⁕⁕       
< 1500 18 217 1    
> = 1500 40 143 3.37 (1.86-6.11) < 0.001 3.78 (1.21-11.8) 0.022 
CRP⁕       
< 150 (ref) 23 216     
> = 150 35 144 2.28 (1.29-4.02) 0.004   
D-Dimer⁕       
< 1.5 (Ref) 14 206     
> = 1.5 44 154 4.20 (2.22-7.94) < 0.001   
Creatinine⁕       
< = 1.2 (Ref) 19 264     
>1.2 39 96 5.64 (3.11-10.24) < 0.001   
Type of admission unit       
ICU ⁕⁕ 40 22 34.14 (16.9-69) < 0.001 3.99 (1.22-13) 0.022 
SCU 17 123 0.78 (0.43-1.46) 0.468   
Ward ⁕ 1 211 0.012 (0.001-0.09) < 0.001   
Treatment       
NIV⁕ 34 83 4.72 (2.65- 8.42) < 0.001   
Invasive ventilation⁕ 36 22 25.14 (12.69-49.80) < 0.001   
Oxygen support⁕ 57 204 43.5 (5.97-318.24) < 0.001   
Systemic steroids⁕ 50 187 5.78 (2.67- 12.54) < 0.001   
Tocilizumab⁕ 19 66 2.21 (1.20-4.07) 0.01   
Complications present (vs absent)      
ARDS⁕ 51 62 35.01 (15.1- 80.8) < 0.001   
Septic Shock⁕⁕ 46 10 134 (54.89- 327.9) < 0.001 13.27 (3.78-46.65) < 0.001 
MODS⁕⁕ 34 6 83.5 (31.96- 218.58) < 0.001 8.60 (2.08-35.64) 0.003 
Nosocomial Infection⁕ 29 27 12.33 (6.46-23.55) < 0.001   
AKI⁕⁕ 47 43 31.39 (15.13-65.13) < 0.001 5.52 (1.78-17.06) 0.003 
NSTEMI⁕ 21 21 9.16 (4.58-18.33) < 0.001   
Median Length of stay in 
days⁕ (IQR) 8 (3-14) 5 (3-9) 1.04 (1.01-1.07) 0.016   
⁕ significant on univariable analysis at p-value<0.05; ⁕⁕ significant on multivariable analysis at p-value<0.05. CKD: Chronic kidney disease; CXR: Chest X-ray; 
NLR: neutrophil to lymphocyte ratio; CRP: C-reactive protein; ICU: Intensive care unit; SCU: Special care unit; NIV: Non-invasive ventilation; ARDS: Acute 
respiratory distress syndrome; MODS: Multi-organ dysfunction Syndrome; AKI: Acute kidney injury; NSTEMI: Non-ST elevation myocardial infarction. 
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Presence of septic shock (AOR = 13.2; 95%CI: 3.78-
46.65), multi-organ dysfunction (AOR= 8.6 (95%CI: 
2.08- 35.64), acute kidney injury (AOR= 5.52; 95%CI: 
1.78-17.06), admission to the ICU (AOR = 3.99; 
95%CI: 1.22- 13), age ≥ 60 years (AOR= 3.25; 95%CI: 
1.07 – 9.89) serum ferritin ≥ 1500ng/ml (AOR= 3.78; 
95%CI: 1.21 -11.8) and NLR ≥ 5 (AOR = 4.04; 
95%CI:1.14-14.35) were independently associated with 
mortality. None of the treatment options were found to 
have any significant benefit on mortality or length of 
stay. We tested for interactions between age, sex, and, 
diabetes but these were not significant. 
 
Discussion 
Our study highlights some of the differences in 
outcomes and severity seen in LMIC compared to 
previously reported studies. While our overall inpatient 
mortality was 13% and the patients had a significant 
burden of comorbid conditions, some of the “classic” 
risk factors for mortality were not found. While 
comorbid conditions were associated with mortality on 
univariable analysis, these were not found to be 
independent predictors of death on multivariable 
analysis. This is in contrast to most studies, which 
report an independent association of mortality with 
comorbid conditions such as diabetes, chronic kidney 
disease, and malignancy [11–15]. This is quite 
interesting considering the greater proportion of our 
cohort were diabetics (36% compared to 7.5 to 19% in 
China and 13 % in Italy). Few studies report a similar 
absence of statistically significant association between 
comorbid conditions and severity[16, 17]. Possibly, the 
baseline control of comorbid conditions may have 
influenced outcomes. For instance, uncontrolled 
inpatient hyperglycemia, with or without known 
diabetes, is an independent predictor of worse outcomes 
[18–20]. Data on baseline and inpatient control of 
comorbid conditions was not collected in our study. 
Future analyses of the association of outcomes with 
comorbid conditions should be stratified according to 
comorbid control to better describe the possible 
relationship. In our study, in-hospital mortality was 
13.88%, and the mean length of hospitalization was 
7.37 days. In-hospital mortality has been reported to be 
28% from tertiary care centers in China [21], 21.7% 
from centers in New York [13], 20% from Iran [22], and 
35% in-hospital mortality from a single center study in 
Italy [23]. Our ICU mortality was 58.8% which is 
comparable to the estimated case fatality rate ranging 
from 40% to 59% of ICU admissions who require 
invasive mechanical ventilation [24–26]. However, 
there has been wide variability in data reported from 
different parts of the world. ICU mortality was reported 
as 26 % from large multicenter case series from 
Lombardy, Italy [27], 35.8%% from a National cohort 
study from the UK [28], 31% in a multicenter study 
from Spain [29], 53% from a large center in New York, 
USA [30], and 56% from a tertiary care center in India 
[31]. The heterogeneity in these figures is explained by 
limited ICU resources particularly in pandemic 
epicenters and may have been influenced by the age of 
the affected population [24]. Our ICU mortality rate 
parallels that which is reported from large centers in 
both US and India. To better characterize differences in 
mortality, we determined the risk factors for death 
among hospitalized patients. Our study showed that 
multi-organ dysfunction, septic shock, and admission to 
the intensive care unit on presentation were associated 
with mortality. These are similar to risk factors reported 
from other regions across the globe, though individual 
risk factors have varied [13,32]. Similarly, acute kidney 
injury was also an independent predictor of mortality as 
has been reported from various countries as well [32]. 
Second, on multivariate analysis of laboratory 
parameters at presentation, only the NLR was found to 
have a statistically significant association with both 
disease severity and mortality. CRP, LDH, and 
creatinine were found to be associated with disease 
severity alone, whereas ferritin was associated with 
mortality alone. Associations between higher levels of 
biochemical and hematological markers of 
inflammation and organ dysfunction with increasing 
disease severity and mortality was also observed, 
consistent with literature from other centers [33]. 
However, our study supports the early use of NLR as a 
single marker for risk stratification for both disease 
progression and mortality, making this cost-effective 
and readily available tool especially valuable in 
resource-limited settings. Similar to other studies [34–
37], we also found age to be a risk factor for severe 
disease. A possible explanation for this may be the 
impaired immune responses with advancing age as both 
innate and cell-mediated immune mechanisms decline 
to cause unchecked viral replication and exaggerated 
proinflammatory cytokine production [38,39]. On the 
other hand, we did not find an association with the male 
sex and poor outcomes, and neither did we find the age 
and sex interaction term to be significant. To 
understand this further, we evaluated mortality: sex 
ratios across all age groups; 7.6 for the age interval 50-
70 years compared with 2.3 for the age interval of 71-
90 years. This highlights the need for disaggregated 
data to better understand the interaction between 
biological sex and age and its association with mortality 
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[40]. We found a greater incidence of nosocomial 
infections compared to other studies [41–43]. 
Nosocomial infections were also associated with 
mortality in univariable analysis, which may be related 
to immunosuppression with tocilizumab and steroids. 
This may be an important observation in the context of 
low-middle income countries where the incidence of 
nosocomial infections is higher and can contribute to 
poor outcomes [44] in COVID-19. Our study highlights 
important differences in factors associated with severity 
and mortality particularly relevant to a low-middle 
income country whereby despite a high prevalence of 
diabetes and increased incidence of nosocomial 
infections there was comparatively lower in-hospital 
mortality. One of the reasons for this could be that 66% 
of the patients were less than 60 years of age and 
therefore as opposed to developed countries, a 
relatively younger age group was affected. This may 
also explain the case fatality rate from Pakistan which 
has remained around 2-3 % which is considerably lower 
than Italy and Iran but similar to CFR reported from 
China and India [45] There has been considerable 
speculation on the reasons behind this phenomenon and 
it has been postulated that both genetic and 
environmental factors may have a role despite the 
resource constraints [10]. However, some limitations 
need to be recognized that may limit generalizability. 
These include retrospective data collection, single-
center nature of the study. Moreover, the varying 
treatment protocols, as more data became available, 
influenced clinical practices, and may have had bearing 
on the results of the study.. Notwithstanding limitations, 
the present study emphasizes the key epidemiological 
differences in the nature of the outbreak experienced in 
Pakistan which need to be explored and validated in 
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